Literature DB >> 22339182

Trichomonas vaginalis: treatment questions and challenges.

W Evan Secor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22339182      PMCID： PMC4670086          DOI： 10.1586/eri.11.159

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN： 1478-7210            Impact factor:   5.091


× No keyword cloud information.
  20 in total

1.  Utility of antimicrobial susceptibility testing in Trichomonas vaginalis-infected women with clinical treatment failure.

Authors:  Elizabeth A Bosserman; Donna J Helms; Debra J Mosure; W Evan Secor; Kimberly A Workowski
Journal:  Sex Transm Dis       Date:  2011-10       Impact factor: 2.830

2.  In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis.

Authors:  Andrea L Crowell; Kolby A Sanders-Lewis; W Evan Secor
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 3.  Trichomonas vaginalis infection: the most prevalent nonviral sexually transmitted infection receives the least public health attention.

Authors:  Barbara Van der Pol
Journal:  Clin Infect Dis       Date:  2006-11-27       Impact factor: 9.079

4.  Trichomonas vaginalis infection: can we afford to do nothing?

Authors:  R Scott McClelland
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

5.  Anaphylaxis due to metronidazole with positive skin prick test.

Authors:  T Asensio Sánchez; I Dávila; E Moreno; E Laffond; E Macías; A Ruiz; F Lorente
Journal:  J Investig Allergol Clin Immunol       Date:  2008       Impact factor: 4.333

6.  Molecular epidemiology of metronidazole resistance in a population of Trichomonas vaginalis clinical isolates.

Authors:  L J Snipes; P M Gamard; E M Narcisi; C B Beard; T Lehmann; W E Secor
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

7.  Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition.

Authors:  R Scott McClelland; Laura Sangare; Wisal M Hassan; Ludo Lavreys; Kishorchandra Mandaliya; James Kiarie; Jeckoniah Ndinya-Achola; Walter Jaoko; Jared M Baeten
Journal:  J Infect Dis       Date:  2007-01-22       Impact factor: 5.226

8.  Hydrogenosomes of laboratory-induced metronidazole-resistant Trichomonas vaginalis lines are downsized while those from clinically metronidazole-resistant isolates are not.

Authors:  Janelle M Wright; Richard I Webb; Peter O'Donoghue; Peter Upcroft; Jacqueline A Upcroft
Journal:  J Eukaryot Microbiol       Date:  2009-12-10       Impact factor: 3.346

9.  The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004.

Authors:  Madeline Sutton; Maya Sternberg; Emilia H Koumans; Geraldine McQuillan; Stuart Berman; Lauri Markowitz
Journal:  Clin Infect Dis       Date:  2007-10-15       Impact factor: 9.079

10.  Management of trichomonas vaginalis in women with suspected metronidazole hypersensitivity.

Authors:  Donna J Helms; Debra J Mosure; W Evan Secor; Kimberly A Workowski
Journal:  Am J Obstet Gynecol       Date:  2008-01-25       Impact factor: 8.661
View more
  9 in total

1.  Druggability of the guanosine/adenosine/cytidine nucleoside hydrolase from Trichomonas vaginalis.

Authors:  Rayyan Alam; Allen T Barbarovich; Wagma Caravan; Mirna Ismail; Angela Barskaya; David W Parkin; Brian J Stockman
Journal:  Chem Biol Drug Des       Date:  2018-06-19       Impact factor: 2.817

Review 2.  A review on Trichomonas vaginalis infections in women from Africa.

Authors:  Nonkululeko Mabaso; Nathlee S Abbai
Journal:  S Afr J Infect Dis       Date:  2021-06-10

3.  Hydrogenosome metabolism is the key target for antiparasitic activity of resveratrol against Trichomonas vaginalis.

Authors:  Natalia Mallo; Jesús Lamas; José M Leiro
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

4.  Evaluation of the effect of miltefosine on Trichomonas vaginalis.

Authors:  Débora Afonso Silva Rocha; Ivone de Andrade Rosa; Wanderley de Souza; Marlene Benchimol
Journal:  Parasitol Res       Date:  2013-12-22       Impact factor: 2.289

Review 5.  Getting trichy: tools and approaches to interrogating Trichomonas vaginalis in a post-genome world.

Authors:  Melissa D Conrad; Martina Bradic; Sally D Warring; Andrew W Gorman; Jane M Carlton
Journal:  Trends Parasitol       Date:  2012-12-05

6.  Endobiont viruses sensed by the human host - beyond conventional antiparasitic therapy.

Authors:  Raina N Fichorova; Yujin Lee; Hidemi S Yamamoto; Yuko Takagi; Gary R Hayes; Russell P Goodman; Xenia Chepa-Lotrea; Olivia R Buck; Ryan Murray; Tomasz Kula; David H Beach; Bibhuti N Singh; Max L Nibert
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

7.  Deazapurine Nucleoside Analogues for the Treatment of Trichomonas vaginalis.

Authors:  Manal J Natto; Fabian Hulpia; Eric R Kalkman; Susan Baillie; Amani Alhejeli; Yukiko Miyamoto; Lars Eckmann; Serge Van Calenbergh; Harry P de Koning
Journal:  ACS Infect Dis       Date:  2021-05-11       Impact factor: 5.578

Review 8.  Different Drugs, Same End: Ultrastructural Hallmarks of Autophagy in Pathogenic Protozoa.

Authors:  Yasmin Pedra-Rezende; Isabela S Macedo; Victor Midlej; Rafael M Mariante; Rubem F S Menna-Barreto
Journal:  Front Microbiol       Date:  2022-03-29       Impact factor: 5.640

9.  Discovery of Ligand-Efficient Scaffolds for the Design of Novel Trichomonas vaginalis Uridine Nucleoside Ribohydrolase Inhibitors Using Fragment Screening.

Authors:  Shannon Auletta; Wagma Caravan; Julia K Persaud; Samantha F Thuilot; Dean G Brown; David W Parkin; Brian J Stockman
Journal:  ACS Omega       Date:  2019-09-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.